Glaukos Reports Preliminary Q4 and 2025 Results, Reaffirms 2026 Revenue Guidance

Published on January 15, 2026
ALISO VIEJO, Calif.—Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, has announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2025, and reaffirmed its full year 2026 revenue guidance. The company advised that total net sales for the fourth quarter of 2025 are expected to be approximately $143 million, a reported increase of 36 percent compared with the same period in 2024. Results are expected to comprise approximately $86 million in U.S. glaucoma net sales, including iDose TR net sales of approximately $45 million, approximately $33 million in international glaucoma net sales, and approximately $24 million in corneal health net sales.
Continue reading on website
Other news

Sight Sciences Releases Preliminary Q4 and 2025 Financial Results

January 15, 2026
MENLO PARK, Calif.—Sight Sciences, Inc., (Nasdaq: SGHT), an eyecare technology company, has reported select preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2025. Fourth quarter 2025 total revenue is expected to be in the range of $20.3 million to $20.4 million, the company advised, an increase of 7 percent at the estimated midpoint compared with

Eyebot and The Framery at 1-800 Contacts Partner to Create End-to-End Retail Optical Experience

January 15, 2026
LAS VEGAS—Eyebot, a developer of automated vision testing technology, and The Framery, an online platform for prescription glasses at 1-800 Contacts, have announced a new partnership to offer a joint, end-to-end optical retail experience, which is expected to launch later this year.